Page last updated: 2024-10-24

ventricular system development

Definition

Target type: biologicalprocess

The process whose specific outcome is the progression of the brain ventricular system over time, from its formation to the mature structure. The brain ventricular system consists of four communicating cavities within the brain that are continuous with the central canal of the spinal cord. These cavities include two lateral ventricles, the third ventricle and the fourth ventricle. Cerebrospinal fluid fills the ventricles and is produced by the choroid plexus. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343]

The ventricular system, a complex network of interconnected cavities within the brain, plays a crucial role in cerebrospinal fluid (CSF) production, circulation, and removal. Its development is a tightly orchestrated process that begins early in embryonic life and continues throughout gestation.

The ventricular system arises from the neural tube, the embryonic precursor to the central nervous system. As the neural tube closes, its lumen expands to form the four primary ventricles: the lateral ventricles, the third ventricle, the fourth ventricle, and the cerebral aqueduct connecting the third and fourth ventricles.

**Early Stages of Ventricular Development:**

* **Neural tube formation:** The neural tube, the foundation of the central nervous system, develops from the ectoderm during the third week of human gestation. The lumen of the neural tube will eventually form the ventricular system.
* **Neuroepithelial cells:** The inner lining of the neural tube is composed of neuroepithelial cells, which are pluripotent and capable of differentiating into various cell types, including neurons, glial cells, and ependymal cells. These cells are responsible for forming the ventricular walls and lining.
* **Expansion of the lumen:** As the neural tube closes, the lumen expands, forming the central canal of the spinal cord and the ventricular cavities of the brain.

**Formation of the Primary Ventricles:**

* **Lateral ventricles:** These paired ventricles, the largest in the brain, develop from the expansion of the lumen in the telencephalon (forebrain). They are C-shaped structures with two horns (anterior and posterior) and a body.
* **Third ventricle:** The third ventricle forms from the expansion of the lumen in the diencephalon (midbrain). It connects to the lateral ventricles through the interventricular foramina (foramina of Monro).
* **Fourth ventricle:** The fourth ventricle develops from the expansion of the lumen in the rhombencephalon (hindbrain). It connects to the third ventricle through the cerebral aqueduct and to the central canal of the spinal cord.

**Development of the Choroid Plexus:**

* **Choroid plexus formation:** During the second trimester, specialized capillaries and ependymal cells in the ventricular walls give rise to the choroid plexus, a network of vascular structures responsible for producing CSF.
* **CSF production:** The choroid plexus filters blood and produces CSF, which flows through the ventricles and surrounds the brain and spinal cord.

**Ventricular Development and Neural Cell Differentiation:**

* **Ependymal cells:** The ventricular walls are lined by ependymal cells, specialized epithelial cells that contribute to CSF production and circulation.
* **Neurogenesis:** Neural stem cells in the ventricular zones of the developing brain give rise to neurons and glial cells, which migrate to various regions of the brain.
* **Glial cell development:** Glial cells, including astrocytes and oligodendrocytes, develop from progenitors in the ventricular zones and play crucial roles in supporting and regulating neural function.

**Ventricular Development and Brain Morphogenesis:**

* **Ventricular size and shape:** The size and shape of the ventricular system are critical for brain morphogenesis, determining the overall form and structure of the brain.
* **Ventricular fluid dynamics:** The flow of CSF through the ventricles influences brain development and function by providing nutrients, removing waste products, and regulating pressure within the brain.

**Disruptions in Ventricular Development:**

* **Hydrocephalus:** A condition where CSF accumulates in the ventricles, causing increased pressure on the brain. This can be caused by various factors, including obstruction of the flow of CSF, overproduction of CSF, or impaired absorption of CSF.
* **Neural tube defects:** Defects in neural tube closure can result in various birth defects, including anencephaly (absence of parts of the brain) and spina bifida (defects in the spinal cord).
* **Other disorders:** Other disorders affecting the ventricular system include Dandy-Walker malformation (an abnormal development of the fourth ventricle), holoprosencephaly (failure of the forebrain to divide completely), and ventriculomegaly (enlargement of the ventricles).

The development of the ventricular system is a complex and intricate process that is essential for brain development and function. Understanding the mechanisms underlying ventricular development is crucial for understanding brain development and for developing therapies for brain disorders.
'"

Proteins (2)

ProteinDefinitionTaxonomy
Cystine/glutamate transporterA cystine/glutamate transporter that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9UPY5]Homo sapiens (human)
CDK-activating kinase assembly factor MAT1A CDK-activating kinase assembly factor MAT1 that is encoded in the genome of human. [PRO:DNx]Homo sapiens (human)

Compounds (47)

CompoundDefinitionClassesRoles
gw8510GW8510: 3' substituted indolone as a scaffold for the development of neuroprotective drug; structure in first source
mesalaminemesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols
non-steroidal anti-inflammatory drug
nu6102NU6102: structure in first source
sulfapyridinesulfapyridine : A sulfonamide consisting of pyridine with a 4-aminobenzenesulfonamido group at the 2-position.

Sulfapyridine: Antibacterial, potentially toxic, used to treat certain skin diseases.
pyridines;
substituted aniline;
sulfonamide;
sulfonamide antibiotic
antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic
sulfasalazinesulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
cysteinecysteine;
cysteine zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid
EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
quisqualic acidQuisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis.non-proteinogenic alpha-amino acid
staurosporineindolocarbazole alkaloid;
organic heterooctacyclic compound
apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
cyc 202seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.2,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
serine o-sulfateL-serine O-sulfate : A non-proteinogenic L-alpha-amino acid that is the O-sulfo derivative of L-serine.

serine O-sulfate: RN given refers to (L)-isomer
L-serine derivative;
non-proteinogenic L-alpha-amino acid;
O-sulfoamino acid
homocysteic acidhomocysteic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group has benn oxidised to the corresponding sulfonic acid.

homocysteic acid: promotes growth in hypophysectomized rats; RN given refers to parent cpd

L-homocysteic acid : A homocysteic acid with L-configuration.
homocysteic acidNMDA receptor agonist
2H-pyrazolo[4,3-b]quinoxalin-3-aminequinoxaline derivative
6-bromoindirubin-3'-oxime6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.

6-bromoindirubin-3'-oxime: structure in first source
2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dioneaminotoluene
cgp 60474substituted aniline
cgp 74514a
1,4-dimethoxy-10H-acridine-9-thioneacridines
bms 387032N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source

N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.
1,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
susalimodsusalimod: analogue of sulphasalazine, was designed for use in the treatment of rheumatoid arthritis
wogoninwogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.

wogonin: structure in first source
dihydroxyflavone;
monomethoxyflavone
angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite
alvocidibalvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.

alvocidib: structure given in first source
dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
su 9516
arcyriaflavin aarcyriaflavin A: from marine ascidian, Eudistoma sp.; structure given in first sourceindolocarbazole
palbociclibaminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
cvt 313CVT 313: a potent inhibitor of CDK2 that prevents neointimal proliferation; structure given in first source
nu 61404-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide: a cyclin-dependent kinase inhibitor; structure in first source
erastinerastin : A member of the class of quinazolines that is quinazolin-4(3H)-one in which the hydrogens at positions 2 and 3 are replaced by 1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl and 2-ethoxyphenyl groups, respectively. It is an inhibitor of voltage-dependent anion-selective channels (VDAC2 and VDAC3) and a potent ferroptosis inducer.

erastin: an antineoplastic agent; structure in first source
aromatic ether;
diether;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
quinazolines;
tertiary carboxamide
antineoplastic agent;
ferroptosis inducer;
voltage-dependent anion channel inhibitor
at 75194-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide : A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine.dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
pf 5732286-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one: structure in first sourcequinolines
pha 848125N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide: a cyclin dependent kinase inhibitor
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source
p276-00P276-00: antineoplastic, cyclin-dependent kinase inhibitor; structure in first source
cink4CINK4: cyclin-dependent kinase 4 inhibitor; may have tumor suppression activity; structure in first sourceindoles
ldc067
(R)-DRF053(R)-DRF053 : A member of the class of 2,6-diaminopurines that is 2,6-diamiopurine which is substituted by an isopropyl group at position 9 and in which the amino groups at positions 2 and 6 are substituted by a 1-hydroxybutan-2-yl and 3-(pyridin-2-yl)phenyl groups, respectively (the R enantiomer). A cyclin dependent kinase inhibitor, widely used as its hydrochloride hydrate.2,6-diaminopurines;
phenylpyridine;
primary alcohol;
secondary amino compound
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
pf 3758309PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first sourceorganic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
ribociclibribociclib: inhibits both CDK4 and CDK6
bay 1000394roniciclib: an antineoplastic agent that inhibits cyclin-dependent kinases; structure in first source
abemaciclib
dinaciclibpyrazolopyrimidine
gilteritinibgilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.

gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor
aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
longdaysin
bs-181BS-181: a CDK7 inhibitor with antineoplastic activitypyrazolopyrimidine
on123300ON123300: a protein kinase inhibitor; structure in first source
ly2857785
THZ531THZ531 : A member of the class of indoles that is 5-chloro-4-(1H-indol-3-yl)-N-[(3R)-piperidin-3-yl]pyrimidin-2-amine in which the piperidine NH group is substituted by a 4-{[(2E)-4-(dimethylamino)but-2-enoyl]amino}benzoyl group. It is a first-in-class CDK12 and CDK13 covalent kinase inhibitor with IC50 of 158 nM and 69 nM, respectively.

THZ531: inhibits both CDK12 and CDK13; structure in first source
aminopyrimidine;
enamide;
indoles;
N-acylpiperidine;
organochlorine compound;
secondary amino compound;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
ro 3306RO 3306: structure in first source